• LAST PRICE
    0.4650
  • TODAY'S CHANGE (%)
    Trending Down-0.0259 (-5.2760%)
  • Bid / Lots
    0.4720/ 1
  • Ask / Lots
    0.4948/ 3
  • Open / Previous Close
    0.4891 / 0.4909
  • Day Range
    Low 0.4650
    High 0.4930
  • 52 Week Range
    Low 0.1972
    High 1.2000
  • Volume
    34,303
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.4909
TimeVolumeTOVX
09:32 ET1700.4891
09:33 ET1000.486499
09:37 ET2090.480001
09:42 ET4130.48
09:51 ET1000.480001
09:57 ET4200.4802
10:38 ET1000.4865
11:16 ET16320.4865
11:18 ET16000.48
11:38 ET105690.48
11:39 ET133510.47
11:57 ET1000.4775
12:37 ET1890.484799
01:04 ET10000.47995
01:36 ET3480.4752
01:54 ET1000.484699
03:33 ET1850.48
03:51 ET2500.4824
03:53 ET3000.476
03:55 ET5000.466
04:00 ET8950.465
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTOVX
Theriva Biologics Inc
7.9M
-0.4x
---
United StatesBTTX
Better Therapeutics Inc
8.2M
-0.1x
---
United StatesCMXC
Cell MedX Corp
8.3M
-5.3x
---
United StatesATHE
Alterity Therapeutics Ltd
11.5M
-0.8x
---
United StatesERNA
Eterna Therapeutics Inc
8.4M
-0.4x
---
United StatesCMMB
Chemomab Therapeutics Ltd
8.6M
-0.1x
---
As of 2024-02-25

Company Information

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patients immune system. The Company’s lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Contact Information

Headquarters
9605 Medical Center Drive, Suite 270ROCKVILLE, MD, United States 20850
Phone
734-332-7800
Fax
734-332-7878

Executives

Independent Chairman of the Board
Jeffrey Kraws
Chief Executive Officer, Chief Financial Officer, Director
Steven Shallcross
Independent Director
John Monahan
Independent Director
Jeffrey Wolf

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.9M
Revenue (TTM)
$0.00
Shares Outstanding
17.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.45
EPS
$-1.18
Book Value
$3.61
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.